Tiziana Life seals deal with Novimmune
Tiziana Life Sciences has been granted an exclusive license to develop and commercialise Novimmune SA's CD3 receptor monoclonal antibody foralumab.
FTSE AIM All-Share
743.26
16:50 28/03/24
Pharmaceuticals & Biotechnology
21,366.25
17:14 28/03/24
Tiziana Life Sciences
58.50p
16:35 20/10/21
Foralumab can be utilised for a range of autoimmune and inflammatory diseases, such multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis and rheumatoid arthritis, the group said in a statement.
"This is a transformational deal for Tiziana that broadens our pipeline, immediately converting us to a clinical stage company,” said group chief executive Gabriele Cerrone.
“Foralumab, our new lead pipeline asset, has broad potential applications in a number of important multi-billion dollar markets.
"We look forward to updating the market in the coming months as we evaluate how we wish to progress this exciting molecule."
Tiziana shares rose 7.14% to 52.50p at 11:43 on Monday.